1504 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF ONCOLYTIC ADENOVIRUS-MEDIATED SUICIDE GENE THERAPY PLUS IMRT VERSUS IMRT ALONE IN NEWLY DIAGNOSED, INTERMEDIATE-RISK PROSTATE CANCER
James O. Peabody(Henry Ford Hospital), Benjamin Movsas(Henry Ford Health System), Ron Rodriguez(Johns Hopkins University), Svend O. Freytag(Henry Ford Health System), Mohamed A. Elshaikh(Henry Ford Health System), Hans Stricker(University Hospital of Bern), Mei Lü(Ford Motor Company (United States)), Nilesh Gupta(Henry Ford Health System), Theodore DeWeese, Zhaoli Lane(Henry Ford Hospital)
Cited by 0
Related Papers
Atorvastatin Induction of VEGF and BDNF Promotes Brain Plasticity after Stroke in Mice
|Journal of Cerebral Blood Flow & Metabolism|2005|449
Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
|Clinical Cancer Research|2013|358
Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma
|Modern Pathology|2014|227
ERG gene rearrangements are common in prostatic small cell carcinomas
|Modern Pathology|2011|219